CN103351425B - 散乱蛋白pdz调节剂 - Google Patents

散乱蛋白pdz调节剂 Download PDF

Info

Publication number
CN103351425B
CN103351425B CN201310261484.0A CN201310261484A CN103351425B CN 103351425 B CN103351425 B CN 103351425B CN 201310261484 A CN201310261484 A CN 201310261484A CN 103351425 B CN103351425 B CN 103351425B
Authority
CN
China
Prior art keywords
dvlpdz
binding
polypeptide
peptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310261484.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103351425A (zh
Inventor
迈克.科斯塔
萨克德夫.S.西德休
张映楠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN103351425A publication Critical patent/CN103351425A/zh
Application granted granted Critical
Publication of CN103351425B publication Critical patent/CN103351425B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Image Processing (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
CN201310261484.0A 2006-04-10 2007-04-09 散乱蛋白pdz调节剂 Expired - Fee Related CN103351425B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79067306P 2006-04-10 2006-04-10
US60/790,673 2006-04-10
CN2007800216108A CN101467039B (zh) 2006-04-10 2007-04-09 散乱蛋白pdz调节剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2007800216108A Division CN101467039B (zh) 2006-04-10 2007-04-09 散乱蛋白pdz调节剂

Publications (2)

Publication Number Publication Date
CN103351425A CN103351425A (zh) 2013-10-16
CN103351425B true CN103351425B (zh) 2016-01-20

Family

ID=38537937

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310261484.0A Expired - Fee Related CN103351425B (zh) 2006-04-10 2007-04-09 散乱蛋白pdz调节剂
CN2007800216108A Expired - Fee Related CN101467039B (zh) 2006-04-10 2007-04-09 散乱蛋白pdz调节剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2007800216108A Expired - Fee Related CN101467039B (zh) 2006-04-10 2007-04-09 散乱蛋白pdz调节剂

Country Status (8)

Country Link
US (2) US7695928B2 (https=)
EP (2) EP2002259B1 (https=)
JP (1) JP5290148B2 (https=)
CN (2) CN103351425B (https=)
AU (1) AU2007238186B2 (https=)
CA (1) CA2648322C (https=)
ES (2) ES2487637T3 (https=)
WO (1) WO2007121147A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
KR101278073B1 (ko) * 2008-08-04 2013-06-24 연세대학교 산학협력단 Ｉｄｂｆ의 신규 용도
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
KR102148303B1 (ko) 2012-02-11 2020-08-26 제넨테크, 인크. R-스폰딘 전위 및 그의 사용 방법
GB201220891D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
GB201220901D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
US9520180B1 (en) 2014-03-11 2016-12-13 Hypres, Inc. System and method for cryogenic hybrid technology computing and memory
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0134986A2 (de) * 1983-07-13 1985-03-27 FARMITALIA CARLO ERBA S.r.l. Biologisch aktive Heptapeptide, Mittel, die diese enthalten und Anwendungsverfahren
WO2002090544A2 (en) * 2001-05-04 2002-11-14 Hybrigenics Protein-protein interactions in adipocyte cells (3)
WO2003004604A2 (en) * 2001-07-06 2003-01-16 Genentech, Inc. Phage displayed pdz domain ligands

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8430255D0 (en) 1984-11-30 1985-01-09 Erba Farmitalia Biologically active oligopeptides
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
EP0397834B1 (en) 1988-10-28 2000-02-02 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5688936A (en) * 1992-06-11 1997-11-18 The Regents Of The University Of California Vesicle membrane transport proteins
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
DK0779806T3 (da) 1994-09-09 2000-11-27 Takeda Chemical Industries Ltd Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid
NZ310644A (en) 1995-06-07 1999-08-30 Alkermes Inc Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6294330B1 (en) 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
IL140918A0 (en) 1998-07-27 2002-02-10 Genentech Inc Improved transformation efficiency in phage display through modification of a coat protein
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
WO2004032838A2 (en) 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
MX2007000150A (es) 2004-07-01 2007-03-30 Univ California Inhibicion de moleculas pequenas de la interaccion del domini pdz.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0134986A2 (de) * 1983-07-13 1985-03-27 FARMITALIA CARLO ERBA S.r.l. Biologisch aktive Heptapeptide, Mittel, die diese enthalten und Anwendungsverfahren
WO2002090544A2 (en) * 2001-05-04 2002-11-14 Hybrigenics Protein-protein interactions in adipocyte cells (3)
WO2003004604A2 (en) * 2001-07-06 2003-01-16 Genentech, Inc. Phage displayed pdz domain ligands

Also Published As

Publication number Publication date
EP2343551A1 (en) 2011-07-13
HK1131438A1 (en) 2010-01-22
CN101467039B (zh) 2013-11-06
WO2007121147A2 (en) 2007-10-25
CA2648322C (en) 2017-11-28
CA2648322A1 (en) 2007-10-25
JP2009533465A (ja) 2009-09-17
JP5290148B2 (ja) 2013-09-18
AU2007238186A1 (en) 2007-10-25
CN101467039A (zh) 2009-06-24
AU2007238186B2 (en) 2014-01-09
EP2002259B1 (en) 2012-05-16
CN103351425A (zh) 2013-10-16
US7977064B2 (en) 2011-07-12
ES2385261T3 (es) 2012-07-20
EP2343551B1 (en) 2014-05-28
ES2487637T3 (es) 2014-08-22
EP2002259A2 (en) 2008-12-17
US20080167386A1 (en) 2008-07-10
WO2007121147A3 (en) 2008-01-10
US20100136580A1 (en) 2010-06-03
US7695928B2 (en) 2010-04-13

Similar Documents

Publication Publication Date Title
CN103351425B (zh) 散乱蛋白pdz调节剂
US20140235820A1 (en) METHODS AND COMPOSITIONS FOR MODULATING THE Wnt PATHWAY
US9725490B2 (en) ERAP1-derived peptide and use thereof
EP2111413A2 (en) Htra1-pdz and htra3-pdz modulators
EP1781314A2 (en) Compounds that inhibit hsp90 protein-protein interactions with iap proteins
HK1131438B (en) Disheveled pdz modulators
US20090192289A1 (en) Omi pdz modulators
HK1184473A (en) Methods and compositions for modulating the wnt pathway
Wendt et al. Bicyclic b-Sheet Mimetics that Target the Transcriptional Coactivator b-Catenin and Inhibit Wnt Signaling
KR20140075000A (ko) 지모겐 활성화제

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160120

Termination date: 20190409